Replies to post #192587 on Biotech Values

[DewDiligence]

PULM +14% on PK data for PUR0200 in COPD:

http://finance.yahoo.com/news/pulmatrix-mylan-report-positive-pharmacokinetic-123000564.html

MYL has an option to license the ex-US rights to this program.

[DewDiligence]

PULM +140%(!) on QIDP designation for PUR1900:

http://finance.yahoo.com/news/pulmatrix-drug-candidate-receives-qualified-144500653.html

PUR1900 is intended to treat fungal infections in CF patients.

PULM is the result of a 2015 reverse merger (#msg-114559267).